295 completed, 82 terminated, 51 recruiting, 33 active not recruiting. 518 Phase 1, 169 Phase 2.
Follow Lymphoma, Mantle-Cell: new trials by email Literature Review of Lymphoma, Mantle-Cell trials Research Report on Lymphoma, Mantle-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 10 | 2026-09-29 | 2026-10-14 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma 7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2026-09-01 | 2026-08-26 |
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len, Rituximab plus lenalidomide, Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len - Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 40 | 2026-07-10 | 2026-07-13 |
| A Study of ARC-02 in B-cell NHL ARC-02, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Taiho Oncology, Inc. | 140 | 2026-06-22 | 2026-11-02 |
| A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) LY4152199 - IV - Lymphoma, Non-Hodgkin, B-cell Lymphoma | Phase 1 | Recruiting | Eli Lilly and Company | 215 | 2026-05-28 | 2026-10-08 |
| A Study of APG-3288 in Relapsed/Refractory Blood Cancers APG-3288 - Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 180 | 2026-03-10 | 2026-10-15 |
| This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma LTZ-301 - Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | LTZ Therapeutics, Inc. | 42 | 2026-01-29 | 2026-07-24 |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma JWCAR239, Fludarabine, Cyclophosphamide - B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma | Phase 1 | Not yet recruiting | Peking University Cancer Hospital & Institute | 20 | 2025-07-01 | 2025-06-17 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 27 | 2025-05-29 | 2026-01-30 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies EXS73565 - Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 85 | 2025-03-31 | 2026-08-13 |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies Pirtobrutinib, LV20.19 CAR T cells - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2025-02-06 | 2026-08-06 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Surovatamig, Prednisone (or equivalent), Rituximab - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 408 | 2025-01-30 | 2026-10-28 |
| A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Sonrotoclax, Zanubrutinib - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 258 | 2025-01-23 | 2026-10-26 |
Showing 20 of 518. Sign in to see all of them.
Lymphoma, Follicular (393) · Lymphoma, Large B-Cell, Diffuse (361) · Leukemia, Lymphocytic, Chronic, B-Cell (335) · Lymphoma, B-Cell, Marginal Zone (320) · Lymphoma, Non-Hodgkin (292) · Burkitt Lymphoma (233) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (219) · Lymphoma (211) · Lymphoma, Large-Cell, Immunoblastic (192) · Hodgkin Disease (163) · Waldenstrom Macroglobulinemia (162) · Lymphoma, T-Cell, Cutaneous (115) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (115) · Lymphoma, Large-Cell, Anaplastic (112)
Hemic and Lymphatic Diseases (518) · Immunoproliferative Disorders (515) · Lymphatic Diseases (514) · Neoplasms by Histologic Type (514) · Immune System Diseases (513) · Lymphoproliferative Disorders (506) · Neoplasms (486) · Hematologic Diseases (381) · Lymphoma, B-Cell (363) · Disease Attributes (362) · Pathologic Processes (362) · Pathological Conditions, Signs and Symptoms (362) · Leukemia, Lymphoid (353) · Chronic Disease (342) · Leukemia, B-Cell (329)
Rituximab (74) · Cyclophosphamide (60) · fludarabine phosphate (37) · Lenalidomide (30) · Peripheral Blood Stem Cell Transplantation (30) · ibrutinib (30) · Bortezomib (29) · Filgrastim (29) · fludarabine (24) · Bendamustine Hydrochloride (23) · Etoposide (22) · Cytarabine (17) · Melphalan (15) · Cyclosporine (14) · Mycophenolic Acid (13)
National Cancer Institute (NCI) (69) · City of Hope Medical Center (21) · Fred Hutchinson Cancer Center (20) · M.D. Anderson Cancer Center (18) · Memorial Sloan Kettering Cancer Center (16) · Masonic Cancer Center, University of Minnesota (10) · Mayo Clinic (10) · National Institutes of Health Clinical Center (CC) (10) · Northwestern University (7) · Case Comprehensive Cancer Center (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Barbara Ann Karmanos Cancer Institute (5) · Jonsson Comprehensive Cancer Center (5) · Alliance for Clinical Trials in Oncology (4) · Amgen (4)
United States (428) · China (37) · Italy (29) · France (28) · United Kingdom (27) · Australia (21) · Germany (21) · Spain (21) · Canada (19) · Japan (14) · Poland (13) · South Korea (10) · Switzerland (8) · Belgium (7) · Israel (6)
Ajay Gopal (5) · Roger Strair, MD, PhD (4) · Shivaani Kummar, MD (4) · Claudio G. Brunstein, MD, PhD (3) · Edward A. Sausville, MD, PhD (3) · Jack D. Burton, MD (3) · Jane N. Winter, MD (3) · Kami Maddocks, MD (3) · Kenneth G. Lucas, MD (3) · Robert Kreitman, MD (3) · Tycel J Phillips (3)
PMID 34515338, PMID 34398557, PMID 19238148, PMID 19949018, PMID 20028764, PMID 22002018, PMID 27118452, PMID 32499241, PMID 34780125, PMID 36375120, PMID 10552943, PMID 10764422, PMID 11410496, PMID 11756154, PMID 12171484, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15570084, PMID 16061911, PMID 16135477, PMID 16731764, PMID 17020988, PMID 17119113, PMID 17312328, PMID 17947483, PMID 18327587, PMID 18463792, PMID 18470481, PMID 18509084, PMID 18974373, PMID 19139736, PMID 19179301, PMID 19451403, PMID 19451441, PMID 19652067, PMID 19789320, PMID 19965662, PMID 20952687, PMID 21247755, PMID 21346146, PMID 21403127, PMID 21498721, PMID 21745173, PMID 21816833, PMID 22080968, PMID 22259028, PMID 22308288, PMID 22383795, PMID 22430088
P30CA033572 (16), U01CA076576 (9), P30CA015083 (7), P30CA015704 (7), P30CA016058 (6), P50CA107399 (6), U01CA069912 (6), 2016 (5), P30CA016672 (5), U01CA062487 (5), U01CA062491 (5), U01CA062502 (5), U01CA062505 (5), U01CA099168 (5), 2015 (4)